EMAP-II is a tumor derived cytokine that exerts a wide range of activities on endothelial cells, monocytes and neutrophils. EMAP-II inhibits endothelial cell proliferation, vasculogenesis, neovessel formation, and can induce apoptosis. It is also chemotactic towards neutrophils and monocytes and induces myeloperoxidase activity from neutrophils. Of clinical importance, EMAP-II inhibits angiogenesis of vascular beds and suppresses the growth of primary and secondary tumors without affecting normal tissues. Mature EMAP-II is an 18.3 kDa protein, which is synthesized as the C-terminal portion of a biologically inactive precursor protein containing a propeptide of 146 amino acid residues. Recombinant human EMAP-II is an 18.3 kDa protein consisting of 166 amino acid residues.
Human AIMP1 expressed in E.coli
CAT# CSC-CTK0442-20 (20 μg); CAT# CSC-CTK0442-100 (100 μg)
Greater than 98% as determined by SDS-PAGE and HPLC analysis.
Determined by the apoptotic effect on MCF-7 cells (human breast carcinoma cells) using a concentration of 20-40 ng/ml.
Less than 1 EU/μg.
Lyophilized from a sterile-filtered solution with no additives.
Please centrifuge product briefly before opening the vial. Reconstitute in sterile, ultra-pure water to a concentration of 0.1-1.0 mg/ml. This solution can be diluted into other aqueous buffers and stored at -20°C for future use.
Storage & Stability
The lyophilized powder, though stable at room temperature for up to 3 weeks, is best stored desiccated at -20°C. Reconstituted EMAP-II should be used immediately or stored in undiluted working aliquots at -20°C. Avoid repeated freeze / thaw cycles.
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon.